Identification
Instrument name
HYLORIS
Symbol
HYL
ISIN code
BE0974363955
LEI code
875500LZIWS7QEQE0I73
Exchange / Market
Euronext
Trading location
Brussels
Products family
Stocks
Capitalization compartment
Compartment B
ICB
20103015 Pharmaceuticals
Operation
IPO date
Issue type
Initial Public offering
Price range
EUR 10.00 - EUR 11.50 (inclusive)

Company profile

Hyloris Pharmaceuticals SA specializes in the development and reformulation of existing pharmaceutical products, with a focus on cardiovascular diseases. The company has 2 early stage commercial products : Sotalol IV for the treatment of atrial fibrillation developed in partnership with AltaThera (of which the commercialization in the United States is expected for Q3 2020), and Maxigesic® IV for the treatment of pain co-owned with AFT Pharmaceuticals (of which a number of approvals by European regulatory authorities are expected throughout H2 2020, and the approval by the U.S. FDA is expected for H2 2021, with commercialization in such jurisdictions expected after such approvals). Hyloris Pharmaceuticals SA also operates a portfolio of 12 products (of which 4 are in the cardiovascular space) in various stages of development.

Source: Cofisem - Last Update: 30 Jun 2020
Key figures
Millenium 2019 2018 2017
Net sales 91 91 213
Income from ordinary activities 91 91 213
Operating income -5.274 -5.469 -3.866
Cost (net) of financial indebtedness -415 -339 -146
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -5.768 -6.038 -3.717
Net income (Group share) -5.373 -5.791 -3.717
Fiscal year end 12,19 12,18 12,17
Length of fiscal year (month) 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 30 Jun 2020
Shareholder information
 %
Source: Cofisem - Last Update: 30 Jun 2020